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Abstract 
 Hepatitis B Virus (HBV) is a type of virus that affects the liver. Chronic hepatitis B is 
usually asymptomatic and many HBV carriers remain unaware of their viral status, thereby may 
unknowingly transmit the disease. If left untreated or undetected, it could lead to cirrhosis, 
hepatocellular carcinoma or mortality. Although this virus is endemic in some parts of the world 
such as Asia and Africa, it is important to note that HBV has become a global problem. The 
Centers for Disease Control and Prevention (CDC) in conjunction with the United States 
Preventive Services Task Force (USPSTF) estimates that about 700,000 to 2.2 million people in 
the United States have chronic hepatitis B (CHB) and about 14,000 die yearly as a result of 
complications from the virus. Hence, they recommend that screening be offered to individuals at 
high risk for hepatitis B virus. People at risk include but are not limited to individuals born in 
countries of high HBV endemicity (2%), injection drug users, men who have sex with men, 
HIV positive patients, household and sexual contacts of people with HBV, individuals who are 
incarcerated, and people infected with hepatitis C virus.  
 This Doctor of Nursing Practice (DNP) quality improvement project was conducted at the 
Order of Malta Clinic in Oakland, California, a safety-net clinic that provides free health care 
services to individuals who are uninsured, low income and the working poor in the community. 
This clinic serves a huge population of immigrants (about 90% of their patient population) 
eligible for chronic hepatitis B screening but based on observations and review of patients’ chart, 
it was noted that only about 33% of eligible patients were screened. There is currently no 
protocol for chronic hepatitis B screening at this clinic, instead patients are screened based on 
presenting symptoms. Hence, this project sought to improve the screening rates for chronic 
hepatitis B from 33% to 70% at the Order of Malta clinic using the HBsAg blood test by October 
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2019. This was accomplished by interviewing the providers individually and providing in-service 
training to physicians and nurse practitioners on the current HBV screening guidelines. A 
random retrospective review of patients’ chart was done in order to get a sense of the overall 
percentage of eligible patients that were screened. This included a 3-4 weeks of intervention 
period and 10 weeks of implementation. After the intervention and implementation, patients’ 
charts were once again randomly reviewed in order to evaluate the outcome of the project.  
 The motivation for carrying out this project was to improve the screening rate for chronic 
hepatitis B, and treat individuals with a positive result so as to delay or prevent the sequelae that 
comes with the virus. The long-term benefit would be to improve overall health and wellbeing, 
and also decrease the cost of treating hepatitis B associated complications such as cirrhosis, liver 
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Section II. Introduction 
Problem Description 
 Hepatitis B virus (HBV) is a global health epidemic and a serious health hazard. Hepatitis 
is defined as an inflammation of the liver (CDC, 2014). Hepatitis B virus is a kind of virus that 
attacks the liver, and could cause both acute and chronic disease, and according to the World 
Health Organization, hepatitis B is a life-threatening liver infection caused by the hepatitis B 
virus (WHO, 2018). Hepatitis B virus is spread from individuals who are infected to those who 
are not immune (Teo & Lok, 2018). This could happen through sharing of needles, sexual 
contact, or from mother to baby at birth (CDC, 2015). Teo and Lok (2018) noted that there are 
different modes of transmission of HBV but the predominant mode varies in different 
geographical locations. In high prevalence areas, mother-child transmission remains the most 
predominant mode of transmission while horizontal transmission is predominant in intermediate 
areas; unprotected sexual contact and injection drug use are major modes of transmission in low 
prevalence areas (Teo & Lok, 2018). Hepatitis B virus has a long incubation period of about 30 
to 180 days and an average of 75 days, and it can survive outside of the body for at least 7 days 
(WHO, 2018). When hepatitis B virus enters the body, it could be detected within 30 days during 
the acute phase, if it persists, it could develop into a chronic phase. It is imperative to note that 
acute hepatitis B infection could easily become chronic as it is frequently asymptomatic, and it is 
the leading cause of cirrhosis and hepatocellular carcinoma in the United States and globally 
(CDC, 2014).  
Chronic hepatitis B virus infection, defined as hepatitis B surface antigen (HBsAg) 
positivity for at least 6 months, is a major cause of morbidity and mortality worldwide (CDC, 
2014). Wilkins, Sams, and Carpenter (2019) defined chronic hepatitis B as the persistence of 
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hepatitis B surface antigen for more than six months. They went ahead to state that although 
individuals who have chronic hepatitis B are at risk of hepatocellular carcinoma and cirrhosis, 
that morbidity and mortality are reduced with adequate treatment (Wilkins et. al, 2019). This also 
was supported by the findings of Mitruka et. al (2019), which found that without diagnosis and 
treatment, 15–25% of an estimated 240 million persons with chronic hepatitis B infection 
worldwide will die prematurely from long term sequelae of cirrhosis, liver failure, and 
hepatocellular carcinoma (Mitruka et.al, 2019).  
According to the U.S. Preventative Services Task Force, approximately 700,000 to 2.2 
million persons in the United States have chronic hepatitis B virus infection (USPSTF, 2014).  
An estimated 2 billion people worldwide are infected with HBV and 380 million people are 
chronic carriers. There is also a report of 4.5 million new infections and about 620,000 deaths 
yearly (Lemoine, Nayagam & Thurz, 2013), this number is markedly increasing by the year. A 
more recent data by the World Health Organization showed an estimate of 887,000 HBV related 
deaths in 2015 (WHO, 2018). Campbell et.al (2018) stated that between 850,000 and 2,200,000 
people in the United States are infected with chronic HBV. Most of these individuals were born 
in countries with high HBV prevalence rates which include Asia, Africa, South and Central 
America (Campbell, Lopez, Liu, Bhuket & Wong, 2018). Teo and Lok (2018) found that the 
overall prevalence of chronic hepatitis B is reported to be 3.6%, however, this number varies 
based on the geographical location. The prevalence of chronic HBV ranges from <2% in low 
prevalence areas such as the United States, Canada, and Western Europe to 2-7% in intermediate 
prevalence areas and 8% in high prevalence areas such as Western Africa (Teo & Lok, 2018).  
Even though HBV is highly preventable with the advent of Hepatitis B vaccination or 
immunization which remains the most effective means to prevent HBV transmission (Drutz, 
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2019), the number of people infected remains high.  This clearly points to a gap in screening. 
Hence, the U.S. Preventative Services Task Force (USPSTF) recommends screening for chronic 
HBV in high risk individuals. “High risk” is defined as immigrants from a country of origin with 
a 2% prevalence of chronic HBV, HIV positive patients, intravenous drug users, and previously 
incarcerated individuals (USPSTF, 2014).  
Geographic Distribution of Chronic Hepatitis B Virus 
Hepatitis B virus is found worldwide but differs in endemicity.  According to the World 
Health Organization (See appendix A and B), most of the world’s population live in countries 
where the prevalence of hepatitis B surface antigen (HBsAg) in the general population is high 
(≥8%) or intermediate (27%). The prevalence of hepatitis B virus remains low in certain areas 
of North America, northern and western Europe, the southern Cone of South America, Australia 
and New Zealand (WHO, 2018). The CDC also supports the WHO’s data, which found that 
about 45% of the world’s population live in areas of high hepatitis B endemicity where the 
prevalence is 8% and a lifetime risk of acquiring it is >60%. Another 43% live in areas of 
intermediate endemicity with a prevalence of 2-7% where the lifetime risk of acquiring it is 20-
60%, and only about 12% of the world’s population live in areas of low endemicity where the 
prevalence is <2% with a lifetime risk of <20% (CDC, 2014).  
Screening for Chronic Hepatitis B 
 The most commonly used test for diagnosing acute hepatitis B or detecting carriers is a 
blood test, HBsAg. It is the serologic hallmark of hepatitis B virus infection (Lok, 2018). The 
presence of HBsAg indicates either an acute or chronic infection (CDC, 2018). In order to screen 
for chronic hepatitis B in asymptomatic individuals, hepatitis B surface antigen (HBsAg) and 
hepatitis B surface antibody (Anti-HBs) are recommended (Lok, 2018). While HBsAg indicates 
CHRONIC HEPATITIS B SCREENING  10 
acute or chronic infection, Anti-HBs is a protective antibody that indicates recovery and 
immunity against infection (CDC, 2018). For the purposes of this DNP project, only the HBsAg 
blood test will be used instead of the USPSTF recommendation of using HBsAg, hepatitis B 
surface antibody (Anti-HBs) and Hepatitis B core antigen (Anti-HBc); and this is largely due to 
lack of funding from the clinic. The Hepatitis B core antigen (Anti-HBc) will help distinguish 
between infection versus immunity, as it only appears after HBV infection and not as a result of 
HBV vaccination. Whereas, individuals who have received HBV vaccination have only anti-HBs 
(USPSTF, 2014). Testing for HBsAg will target individuals who test positive whereas testing for 
Anti-HBs will target individuals who are either immune or susceptible and vaccinate the latter. 
Recommendations for future studies will be to test for HBsAg, Anti-HBs and Anti-HBc so as to 
vaccinate susceptible individuals to further prevent transmission.  
   Eligibility Criteria for HBV Screening  
The CDC has the following recommendations of persons or groups eligible for screening 
for chronic hepatitis B virus. This includes:  
persons born in geographic regions with HBsAg prevalence of ≥2%, US born persons not 
vaccinated as infants whose parents were born in geographic regions with HBsAg 
prevalence of ≥8%, injection-drug users, men who have sex with men, persons with 
elevated ALT/AST of unknown etiology, persons with selected medical conditions who 
require immunosuppressive therapy, pregnant women, infants born to HBsAg-positive 
mothers, household contacts and sex partners of HBV-infected persons, persons who are 
the source of blood or body fluids resulting exposures that might warrant post exposure 
prophylaxis (e.g., needle stick injury to a health care worker) and persons infected with 
HIV (CDC, 2008).  
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           Clinic Setting 
 The Order of Malta Clinic in Oakland opened its doors in 2008. It is a nonprofit safety-
net primary care clinic that provides free medical care to the uninsured and low-income patients. 
It is one of the medical service arms of the Sovereign Order of Malta, Western Association, 
U.S.A. The clinic has about 25 volunteer physicians and nurse practitioners, and 35 volunteer 
nurses. They offer an array of medical services and specialties including internal medicine, 
cardiology, neurology, rheumatology, hematology/oncology, otolaryngology, urology, 
gynecology, gastroenterology, podiatry and dermatology (Order of Malta Clinic, 2018). As a 
result of the healthcare crisis in the United States, free clinics such as Order of Malta are highly 
desired by patients and the communities they serve. A recent study that surveyed over 360 clinics 
nationwide found that there is an increase demand and need for free and charitable clinics, 
without which, the uninsured population will not have access to preventive medicine (Birs et. al, 
2016). This clinic sees a huge number of immigrants mostly from Asia and Africa where the 
burden of chronic HBV is endemic. As a safety-net clinic enriched in ethnic minorities, it 
provides a great opportunity for screening for chronic hepatitis B virus.  
   Study Goal  
Currently, at the Order of Malta clinic, patients eligible for chronic hepatitis B are not 
always screened following the CDC recommendations, instead, this clinic screens symptomatic 
patients. Hence, many patients eligible for screening are being missed, and since chronic HBV is 
usually asymptomatic, persons with chronic HBV can still transmit the disease to others 
unknowingly thereby posing additional threats to the general public. Therefore, the goal of this 
project is to improve chronic hepatitis B screening by addressing the gap between current and 
optimal screening. By so doing, more patients will be screened and those with a positive HBsAg 
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will be treated in order to prevent or delay cirrhosis and hepatocellular carcinoma. Richmond, 
Sasadeusz, & Temple-Smith state that if chronic hepatitis B is diagnosed early and managed 
appropriately, that the risk of liver disease and hepatocellular carcinoma will be greatly reduced 
(2018). For the purposes of this project, we will be screening for chronic HBV using only the 
HBsAg test. In Appendix C, some explanations of different types of tests and their 
interpretations are provided, but we are only focusing on the HBsAg test due to funding 
limitations. 
Population, Intervention, Comparison, Outcome and Time (PICOT) 
A survey of 277 providers in different healthcare settings organized by the San Francisco 
Health Improvement Partnership and Hepatitis B Free Campaign found that HBV screening 
remains suboptimal. This was largely attributed to several gaps in providers’ knowledge of 
screening guidelines, moreover, a third of the providers were unaware that HBV therapy reduces 
the risk for the progression of liver disease (Mukhtar et. al. 2017). Hence, the need to educate 
providers as a means to increase knowledge and awareness of hepatitis B, with an expected 
outcome of improving HBV screening rates. The PICOT question for this project therefore is: 
does provider education/training improve chronic hepatitis B screening compared with no 
education within a six months period?  
Description of Search Process 
 In an effort to answer the PICOT question, the following databases were searched: 
Cochrane, CINAHL, PUBMED, DynaMed, and PsychINFO using the keywords hepatitis, 
hepatitis b, hepatitis b virus, chronic hepatitis b, hepatitis b screening, chronic hepatitis b virus 
infection, and hepatitis b prevention. Cochrane database was limited to full text and English 
language, it yielded a total of 110 articles. CINAHL database yielded 365 articles but when 
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limited to English language and year of publication, 260 articles were identified. DynaMed 
yielded 10 articles, and PsychINFO yielded 52 articles. Articles were screened based on their 
titles and/or abstracts and the ones that were selected addressed hepatitis b screening, chronic 
hepatitis B virus or infection.         
     Available Knowledge  
Barriers to HBV Screening 
Two research studies that surveyed 404 Asian-Americans found that barriers to HBV 
screening can occur at different levels which include patient, provider, and resource levels 
(having insurance and a primary care provider (PCP). Lack of knowledge regarding benefits of 
screening was a major patient-related barrier and PCPs not discussing and recommending 
screening tests was found to be a huge physician related-barrier to HBV screening. The authors 
however, stressed the importance of free screening programs for individuals with no insurance to 
facilitate the screening process. They explored some reasons why physicians were not 
recommending HBV screening to patients and found two main reasons: lack of knowledge about 
HBV and screening guidelines or lack of time. Their recommendation for improving HBV 
screening was provider continuing education and the use of electronic health records that has the 
capability of highlighting patients’ country of birth in the demographics section. They concluded 
that screening for HBV is the most important first step in preventing cirrhosis, liver cancer and 
associated mortality (Cheng, Li & Lok, 2016).  
 Another study that identified barriers to chronic HBV screening found that up to 70% of 
chronic HBV carriers were foreign-born immigrants and that about 2 out of every 3 persons 
infected with HBV were not aware that they were infected. For this singular reason, Abara, 
Qaseem, Schillie, McMahon, and Harris (2017) stressed the importance of screening for HBV as 
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a way to decrease chronic HBV health related complications such as cirrhosis and hepatocellular 
carcinoma thereby decreasing both direct and indirect healthcare costs, estimated at $1 billion. 
Although screening was found to be a very cost-effective method of reducing healthcare cost and 
burden, its use still remained low, hence they were of the view that screening for chronic HBV 
should be a public health priority. They also identified gaps in screening for HBV in high risk 
populations, including the fact that among foreign born persons, screening was 11-67% which is 
suboptimal. Despite clinical guidelines from CDC and USPSTF, screening remained low. As 
part of their findings, there were barriers that explained why guidelines were not followed. They 
identified multiple barriers such as patient-related, physician related and system related barriers. 
The authors found that lack of knowledge of chronic HBV, ignorance about screening, language 
barrier and cultural differences were some of the barriers noted on patient-related levels. 
Clinicians, however, missed the opportunities to screen due to lack of knowledge about clinical 
guidelines. Whereas on the system-level barrier, they found that there were very limited hepatitis 
funded programs for uninsured patients making screening somewhat difficult. In an effort to 
increase HBV screening, they urged clinicians to screen during clinical encounters and 
recommended the use of EMR prompts, provider education and standing orders for screening 
and vaccination (Abarra, et.al, 2017). 
 A research study of hepatitis B screening behaviors conducted among Chinese and 
Korean Americans found that even though there is a high prevalence rate of HBV among 
Chinese and Korean Americans, screening rates remain low at 37% to 55% and 32% to 56%, 
respectively. Li et.al (2017) investigated further to learn of the barriers associated with low 
screening of HBV, and found that barriers existed at the individual level, system level, and 
physician level but the most significant level was the barrier that existed at the physician level. 
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Based on this, the authors concluded that a physician screening recommendation significantly 
increased screening rates. Hence, they recommended social marketing (aimed at influencing or 
changing behaviors) as a way to encourage physicians and healthcare providers to increase their 
recommendations of HBV screening (Li et.al, 2017). 
 A study conducted among Vietnamese-Americans (a population considered to be at high 
risk for hepatitis B because they have a high mortality rates of HBV-related liver cancer)       
identified barriers that Asian Americans face to HBV screening.  These barriers included 
personal and cultural related reasons, limited access to healthcare, limited English language 
proficiency and a lack of knowledge on the importance of HBV screening. Ma et. al, (2017), 
found that adopting a community-based approach would help reduce the stigma associated with 
chronic HBV and increase screening rates among this group.  Community-based research study 
approach would provide education on HBV and reduce the stigma associated with it. Similar to 
the findings of other researchers, they also found that patient and provider education would 
increase HBV screening (Ma et. al. 2017). 
Fears of Deportation and Loss of Privacy 
 Fear of deportation and loss of privacy were also identified as barriers that prevented 
Africans living in the US from seeking HBV screening. Sriphanlop et. al. (2014), noted that lack 
of knowledge about HBV and its transmission mode, being asymptomatic and only sought care 
when ill, complexity of the U.S. medical system, and the stigma associated with HBV in the 
community were some of the barriers that prevented Africans in the U.S. from screening for 
HBV. Two unique barriers found among this group that were not found in the Asian-American 
community included the issues of privacy or fear of disclosure and fear of deportation if 
undocumented and tested positive for HBV. Participants feared that health professionals may 
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disclose their HBV status to other community members and family. To increase HBV screening 
rate in this population, the authors’ recommendations therefore were to develop a culturally 
appropriate intervention to target this group, address the issue of confidentiality and clarify any 
misconceptions about deportation in the event of a positive result.  
 A qualitative study on hepatitis B screening among West African Francophone 
immigrants in New York City was conducted. The authors explored barriers hindering this group 
from screening for hepatitis B and found that lack of knowledge about HBV screening, the 
stigma associated with it, cost, religion, attitudes toward health, undocumented status, and fear of 
deportation as major barriers hindering this group. In an effort to increase HBV screening in this 
group, they proposed working alongside religious groups and social networks to spread 
information on hepatitis B screening, and also specifically addressing the issue of deportation or 
detainment (Blanas et.al. 2015). 
Increasing Screening Opportunities 
 Mitruka et. al (2018) conducted a cross-sectional, retrospective analysis and evaluation of 
hepatitis B screening among newly arrived refugees at 99 refugee health clinics in 4 states 
(California, Washington, Minnesota, and Massachusetts). The main aim of their study was to 
improve screening opportunities. They found that among 32,017 persons with valid test results, 
4269 were infected with unknown immune status, 937 were infected, 16,481 were susceptible, 
and 10,186 were immune, remaining 234 were not categorized. As part of their study, it was 
found that the prevalence of hepatitis B infection among refugees was about 10 times higher than 
the U.S. general population. These numbers reinforce the importance of early screening and 
identification of chronic HBV. Their recommendation was for providers to screen eligible 
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individuals, treat infected persons and vaccinate susceptible individuals to further prevent 
transmission.  
 There was also another study that stressed the importance of chronic hepatitis B 
screening. The authors were of the view that complications that arise from chronic hepatitis B are 
costly to manage, hence the importance of screening in order to identify individuals who are 
infected with the virus and at risk of unknowingly transmitting it to others or developing 
complications. They went on to opine that treating hepatitis B virus slows its progression to 
complications such as cirrhosis and liver cancer. Their recommendation was that in order to be 
cost-effective, providers should screen for chronic hepatitis B virus, and treat those who test 
positive for the virus (Wright et. al, 2018).  
Lack of Trust as Barrier 
 A group of authors conducted a pilot screening program of hepatitis B screening at an 
outpatient endoscopy safety-net hospital. They noted that safety-net hospitals are great places to 
screen for chronic hepatitis B virus given the huge number of immigrants that they serve. They 
followed the USPSTF recommended guidelines for screening, and their implementation 
improved HBV screening from 24.5% to 75.6%. Based on their study, several barriers to 
screening were identifiable, including the fact that many minority groups do not trust their 
healthcare providers. They also found that most ethnic minorities did not see the need for 
screening since they were feeling well and asymptomatic. There was also lack of knowledge 
found on both the patients’ side and the providers, the former did not understand the burden of 
the disease, mode of transmission and prevention while the latter lacked awareness of the proper 
screening for this population, hence the reasons for low screening. Their recommendation 
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therefore was that incorporating chronic HBV screening into a safety net clinic would be a great 




  This DNP student undertook a random retrospective review of 240 charts at the clinic, 
and physicians were interviewed individually to identify the barriers for screening for chronic 
HBV. The clinic has noted an increase in the proportion of patients presenting from areas of the 
world where the endemic rate of HBV is considered “high” by the CDC, warranting a chronic 
HBV screening test.  Review of laboratory billing data did not demonstrate an increase in the 
rate of HBV screening tests (typically a single blood HBsAg) resulting in concern for under-
screening at the clinic. Chart review indicated that a gap in screening exists, the current data so 
far indicates about 33% adherence to the screening recommendations per CDC (See Appendix 
F). 
   Theoretical Framework 
 The health belief model, and the theory of social marketing was used to implement this 
project at the Order of Malta Clinic. The health belief model is applicable to the patient 
population that the Malta clinic serves and this will be discussed below. 
The Health Belief Model: 
The health belief model was developed in the 1950s by social psychologists Hochbaum, 
Rosenstock and Kegels at the U.S. Public Health Service in an effort to understand the reasons 
people fail to respond to disease prevention strategies or screening tests. The authors were of the 
view that an individual’s personal belief in either a threat of an illness or effectiveness of 
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recommended health behavior would determine if they would adopt that behavior (LaMorte, 
2018). There are six concepts of the health belief model: perceived susceptibility, perceived 
severity, perceived benefits, perceived barriers, cue to action and self-efficacy.  
Perceived susceptibility: personal belief of the risk or vulnerability of acquiring an illness. 
Perceived severity: personal belief on the seriousness of an illness and consequences if left 
untreated. 
Perceived benefits: personal steps available to avoid or cure illness. 
Perceived barriers: perceived obstacles to follow recommended health options. 
Cue to action: the motivating factor behind accepting a recommended action such as one 
experiencing chest pain.  
Self-efficacy: personal confidence in one’s ability to perform a behavior.  
 Jones et al. (2014) stated that in order for people to change behaviors; barriers, benefits 
and threats need to be addressed. They went on to summarize the concepts of the health belief 
model identified above stating “that people will take action to prevent illness if they regard 
themselves as susceptible to a condition (perceived susceptibility), if they believe it would have 
potentially serious consequences (perceived severity), if they believe that a particular course of 
action available to them would reduce the susceptibility or severity or lead to other positive 
outcomes (perceived benefits), and if they perceive few negative attributes related to the health 
action (perceived barriers)” (Jones et. al. 2014, p. 569). Based on the literature review, several 
cultural and personal beliefs that prevented individuals from HBV screening were identified. 
Hence, by adopting this model, and creating awareness of the dangers of chronic hepatitis B, our 
patient population might be more willing to adopt it.   
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The Theory of Social Marketing: 
 The theory of social marketing was also found to be applicable to our patient population 
at the clinic. Social marketing helps influence health behavior using a wide range of health 
communication strategies such as interpersonal communication and message placement at clinics 
(Evans, 2006). In this study, the author went ahead to state that social marketing uses behavior, 
and persuasion to target health risk behaviors. He identified six stages of social marketing: plan 
strategy, selecting communication channels, developing materials, implementation, assessing 
effectiveness and feedback (Evans, 2006). Placing messages at the clinic aimed at motivating 
patients to ask their healthcare providers of their eligibility for chronic hepatitis B screening 
would serve as a social marketing strategy aimed at influencing health behavior.  
Specific AIM  
By October 2019, about 70% of eligible patients at the Order of Malta Clinic will be 
screened for chronic hepatitis B virus using the HBsAg blood test. Education was provided to 
physicians and nurse practitioners as a reminder on the CDC eligibility criteria for screening. 
Healthcare providers were interviewed individually to gain insights to the barriers of screening 
for chronic HBV. There was a random review of 240 patients’ charts, pre-intervention education 
was provided and charts were once again reviewed post-intervention to determine the outcome 
and success rate.  
Section III. Methods 
Context 
Random retrospective review of 240 charts was undertaken to get a sense of how many 
eligible patients were screened prior to the intervention, this represents about 20-25% of the 
clinic’s population. A pre-and post-intervention was done to determine the impact of this project 
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at the clinic. Guidelines from the CDC, the WHO and existing literature have revealed that 
chronic hepatitis B screening among immigrants is low and this was also an issue that was noted 
at the clinic. Several meetings were held with the medical director of the clinic and some key 
stakeholders. The medium of these meetings included emails, phone calls, and face-face 
meetings. An agreement was reached to carry on with the project with the hopes that it will be 
beneficial to patients and providers. On the one hand, more patients will be screened for chronic 
hepatitis B, and if positive, treatment will be started to prevent or delay end organ damage and 
also minimize transmissions. On the other hand, providers’ knowledge on screening guidelines 
will improve and thus, they will be more willing and comfortable to recommend chronic 
hepatitis B screening to eligible patients.  
Intervention  
Needs Assessment: A series of interviews with clinic providers on a one-on-one basis was 
conducted. This approach was considered over focus groups to ensure that a wide array of 
responses could be collected (i.e., Avoiding a group dynamic where an individual’s responses 
may be overshadowed by another individual’s presence/contribution). Developing this 
instrument was informed by Michie et al’s, twelve domains to consider in designing 
interventions to achieve improved implementation (Michie et.. al.,2004).  Michie et al’s process 
was, at least partially, based on Becker’s Health Belief Model focusing on an aspect of 
motivation (e.g., If a person is highly motivated to an action, they will perform the action) and 
Ajzen’s Theory of Planned Behavior whereby beliefs affect intention which plays a major role in 
carrying out an action (Becker, 1974, Ajzen, 1971). 
  Potential interview questions that were administered to clinic providers were identified, 
vital questions were selected following Fishbein et al’s suggestion that three domains are 
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necessary and sufficient for the engagement of a target behavior: intention, lack of environmental 
constraints, and the actual skill needed to perform the behavior. The Com-B framework was used 
to identify barriers and enablers related to the capability, opportunity, and motivational aspects 
of HBV screening (Fishbein et al. 1975). While the interview guide is essential to investigating 
the implementation of chronic HBV screening practices, the aim was to further apply the 
information gathered toward an intervention to increase HBV screening rates. To that end, 
interview questions related to social influences were included, and using the COM-B framework, 
social influences from clinic opinion leaders were identified as a major potential enabler of 
behavior in the Malta clinic environment (Michie et.al, 2004).  
Contextually, 2 clinic opinion leaders that have provided service at the clinic for the longest 
time were identified. They were available on the most days (4 out of 5 days that the clinic is open) 
and were often sought after for their opinion on patient management both clinically and 
logistically/administratively. The process of instrument development is conceptually diagramed in 
Appendix K. An interview guide is presented with the construct and domains targeted by each 
question and its associated opportunity for change. This tool allows for specific answers to be 
elicited following the table-based format with a summary table denoting the provider, overall 
themes that arise from the interview, and representative quote(s) following the example in 
appendix L. 
Educational Intervention: A 30-minute poster presentation was provided to physicians, nurse 
practitioners and staff at the clinic. This was done over a course of 3-4 weeks at different times 
in order to reach multiple providers. This presentation covered the importance of screening for 
chronic HBV, the eligibility criteria and what test to order.  Also, healthcare providers were 
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provided with a laminated copy of eligibility criteria/screening tool and list of countries of birth 
to screen for, as a quick reference guide (see appendix B). 
Written Protocol: There was also a written protocol for chronic HBV screening at the Order of 
Malta clinic. This written protocol included the screening tool and the test to order for the screening 
which in this regard was the HBsAg test. 
Policy for Referral: The clinic is willing to treat eligible patients with a positive HBsAg test, 
hence, no further referral will be needed at this time. Patients will only be referred for further 
treatment if there is an indication of end organ damage or other complications which the clinic 
would not be able to manage due to limited funding and resources.  
Follow-up: All follow-up will occur at the clinic unless complications arise, which is not 
anticipated at this time.  
Patient Education: There were visual messages posted in the waiting area at the clinic and in 
every examination room on chronic hepatitis B, its risks, and benefits of screening to avoid long 
term sequelae. This message was targeted to patients to encourage them to ask their providers 
about chronic hepatitis B screening.  
Study of the Intervention 
 The purpose of this project was to improve chronic hepatitis B screening at the Order of 
Malta clinic in Oakland, California. The clinic would follow CDC recommendations to screen 
eligible patients at the clinic, which for the most part accounts for about 90% of the patients’ 
population. Eligible patients would be screened regardless of age, gender and family history. 
Outcomes Measurement 
Outcomes were measured based on the following: 
1. The number or percentage of patients screened before and after the intervention. 
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2. Increase in screening eligible patients from baseline of roughly 33% to about 70% by 
October 2019.  
3. Increase in providers’ knowledge of CDC guidelines of chronic hepatitis B screening. 
                    GANTT Chart 
The timeline for this project was from December 2018 to December 2019 (see Appendix 
G). The GANTT chart provided a visual image of when the project was initiated, the different 
stages through the final stage. It also provided an illustration of the clinical coursework that were 
completed alongside the completion of this project. The GANTT chart was used to ensure that 
this project stayed on track since there are timeframe/timeline for each milestone. The initial plan 
for this project was to focus on hepatitis B screening, diagnosis and treatment but after meeting 
with the clinic leadership, an agreement was reached to focus only on the screening of chronic 
hepatitis B which is what the clinic needs at this time.     
Strengths, Weakness, Opportunities, and Threats (SWOT) 
A SWOT analysis helped in identifying the strengths, weaknesses, opportunities and both 
internal and external threats facing this project. One of the strengths of this project will be cost 
saving in the long run because the cost of screening for hepatitis B is far more beneficial than the 
cost of treating it. It also provided training opportunities for physicians and nurse practitioners at 
the clinic to stay abreast of current CDC recommendations of chronic hepatitis B. This ensured 
that providers remained consistent in screening eligible patients for chronic hepatitis B. One 
weakness that this project faced was time constraints in trying to provide the different sessions of 
the training to providers. There were several opportunities that came with this project. Chronic 
hepatitis B screening was improved (although not to the desired goal), thereby enhancing 
outcomes. Providers’ knowledge on screening guidelines was also improved, communication 
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between providers and patients also improved. One major threat faced in the conduct of this 
project was compliance on the part of the providers since change is somewhat difficult to adopt. 
A constant reminder was needed in order to ensure that the providers did not fall back to the 
status quo. Sustainability was another threat faced in the completion of this project because most 
of the providers at the clinic are on a volunteer basis. The question here becomes who continues 
to ensure that the CDC guidelines for hepatitis B screening continues to be followed. (See 
Appendix J). 
      Work Breakdown Structure  
This project was divided into five different parts (see appendix H). The first part 
identified the problems or issues that were addressed. In this case, the first issue was inadequate 
screening for chronic hepatitis B and finding ways to improve this screening at the clinic. The 
second step involved the identification of key stakeholders. For the purpose of this project, the 
stakeholders were physicians, nurse practitioners, patients, nurses and clinic leadership. The third 
phase was the planning phase. During the planning phase, training schedules were mapped out, 
providers were trained/educated over a 3-4 weeks span on CDC guidelines and 
recommendations. There was also a one on one interview of providers to identify barriers to 
hepatitis B screening. The fourth stage was the implementation phase. This step was undertaken 
over a 2-3 months period in order to provide ample time for providers to incorporate the 
screening into their practice and routine. The final phase of this project was the evaluation phase. 
The purpose of this stage was to determine whether or not there were positive or negative 
outcomes.  
Financial Plan 
The financial portion of this project is presented below: 
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 Retrospective review of 240 patients’ charts for 30 hours, this writer’s hourly income 
estimated at $60 per hour. 
 Average time to order hepatitis B screening by physicians and nurse practitioners was 
estimated at 15 minutes, hourly pay estimated at $90. Therefore, they spent $22.50 of 
their hourly income ordering hepatitis B screening test. 
 Each hepatitis B surface antigen test (HBsAg) costs $14.20. 
 Weekly review of charts post-intervention of another 240 charts to evaluate the 
outcome/impact of the project was estimated to be 30 hours. 
 Expense of paper, supplies, ink, lamination and poster was approximately $250. 
Profit and Loss 
The breakdown of loss associated with this project is provided below: 
 The writer’s time in data collection, meetings, and training clinic staff: 
o $60/hour x 60 hours for pre-and post-chart review = $3,600 
 Hourly pay for medical staff at the clinic to assist: 
o $20/hour x 20 hours = $400 
o Cost of paper, lamination, ink, poster and other supplies = $250 
Assumed Cost Savings/Avoidance 
A key recommendation is to screen eligible patients using the hepatitis B surface antigen 
(HBsAg) 
 The cost of one HBsAg test was $14.20, and the average time to order one test was 15 
minutes which resulted in about $22.50 of the providers’ hourly salary.  
o 58 HBsAg tests were ordered, 58 x $14.20 = $823.60 
o Providers’ time = $22.50 x 58 = $1,305 
CHRONIC HEPATITIS B SCREENING  27 
Although the economic impact of treating hepatitis B related complications has not been well 
studied, an estimate of its annual cost is listed below: (see Appendix Q for more information). 
 The average cost of treating one case of chronic hepatitis B is estimated at $761, 
compensated cirrhosis is $227, decompensated cirrhosis is $11,459, liver transplant is 
$86,552, transplant care >12 months following transplant is $12,560, and hepatocellular 
carcinoma is $7,533 (Lee, Veenstra, Iloeje, & Sullivan, 2004).  
Communication Matrix 
As part of this project, stakeholders were identified which include but not limited to 
physicians, nurse practitioners, registered nurses, patients, clinic administrator and office staff. 
There were several back and forth communication involving this writer and the clinic 
administrators, staff, physicians, nurse practitioners, academic supervisor and the second 
academic supervisor. Communication took place on an as needed basis via emails, phone calls, 
zoom, text messages and face to face meetings. After multiple communication, an area of interest 
was identified, and a timeline was developed. The project kicked off after getting an approval 
from the agency (see Appendix M). Multiple educational/training sessions on CDC’s guidelines 
were presented to providers, clinic administrator and clinic staff (See Appendix P). Laminated 
copies of screening tools (see Appendix O) were provided to healthcare providers, and were also 
posted in every patient’s room and nursing station for easy reference. 
Analysis 
 Microsoft Excel was used to analyze data collected during this project. Charts and tables 
were also utilized to provide clarification on the findings on the data analyzed in this project. 
Percentages were used to demonstrate clear and concise results obtained from data collection.  
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Ethical Considerations  
 Some ethical concerns were addressed during the course of this project. Screening for 
chronic hepatitis B followed the recommended guidelines as stipulated by the Centers for 
Disease Control and Prevention. From a clinical standpoint, clinicians at the clinic did not always 
screen for chronic hepatitis B based on the recommendations, individual choices were made to 
offer screening if patient had other risk factors. This might have had to do with the fact that 
USPSTF rated HBV screening as grade B, indicating that it is recommended to screen only in 
high risk individuals. (See Appendix N). For this reason, clinicians often used their personal 
judgment to determine which individuals need screening. This, however poses a clinical ethical 
concern and in order to address this, clinicians are encouraged to follow the hepatitis B screening 
guidelines to screen patients at high risk for chronic hepatitis B. The different grading scale 
communicates the importance of a recommended screening to providers (USPSTF, 2018). The 
United States Preventive Services Task Force (USPSTF) recommends HBV screening in persons 
at high risk. This recommendation is in line with the American Association for the Study of 
Liver Diseases (AASLD) and the Center for Disease Control and Prevention (CDC) guidelines 
(Mukhtar et.al. 2017). 
 Another ethical concern that usually arise with a project of this kind is the issue of 
privacy but in this case, it was not a concerning factor because patients’ identifiers such as 
names, date of birth, and medical record numbers were not used. Country of origin or regions 
were used as a major identifier for screening high risk patients.  
Jesuit Values and ANA Ethical Standards Ethical Considerations  
Hepatitis B screening offered by clinicians would improve patients’ health in the long run 
because patients exhibiting positive hepatitis B would be treated and this will avert long term 
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damage of hepatitis B. This relates to the American Nurses Association’s ethical standard that 
states that “the nurse promotes, advocates for, and protects the rights, health, and safety of the 
patient.” (ANA, 2015). This is also in line with the Jesuit values of cura personalis which means 
care for the whole person. Cura personalis recognizes an individual as a whole, the body, heart 
and soul and promotes the dignity of every person (Otto, 2009). Following the CDC’s guidelines 
to screen for chronic hepatitis B would ensure that patients who are eligible for screening are 
taken care of, thereby promoting their individual dignity and caring for the whole person.  
Section IV. Results 
                 Pre-Intervention Results 
 A random retrospective review of 240 patients’ charts was undertaken prior to the 
intervention, 92 patients were eligible for chronic hepatitis B virus screening, 40 patients were 
not eligible and 108 patients had unknown eligibility status. The reason for this high number of 
unknown eligibility status was due to inadequate information obtained from patients’ charts. Out 
of the 92 patients that were eligible, only 30 patients were screened and this represented 
approximately 33% of the patients.  
    Post-Intervention Results  
 A post-intervention review of charts was done on a weekly basis to evaluate the effect of 
the intervention. Charts of patients who were seen the previous week were reviewed, data 
collected and analyzed. Charts were reviewed over 10 weeks and analysis of this data did not 
show a significant increase in the screening rate. Another 240 patients’ charts were reviewed, 
112 patients were found to be eligible for chronic hepatitis B virus screening, 32 patients were 
not eligible and 96 patients had unknown eligibility status. 58 out of 112 eligible patients were 
screened and this was approximately 52% of eligible patients. This represented a 19% increase 
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from baseline of 33%. Although this project had aimed at improving the screening rate to about 
70%, only a 52% increase was noted and this was largely due to certain limitations that will be 
discussed in the limitation section.  
    Follow up Post-Intervention 
Extra efforts were made to ensure the success of this project. When it was noted that the 
screening was not occurring at the expected rate, some of the nurse volunteers were trained one-
to-one on the screening tool on how to determine patients’ eligibility status based on chart 
review. The nurse volunteers were encouraged to pull charts of patients who were to be seen the 
following day and tagged them for the provider that would be seeing the patient. This extra step 
was meant to serve as a reminder for providers to remember to screen eligible patients based on 
their eligibility status. This extra effort was not very welcoming as the nurse volunteers already 
had so much to accomplish in a given day. Hence, it did not make any significant contribution to 
the results of this project.  
Section V. Discussion  
Summary 
 The aim of this project was to improve hepatitis B screening rate from baseline of about 
33% to about 70% but this aim was not quite achieved, instead the screening rate was only 
improved to about 52% which represented a 19% increase. The reason for this minimal level of 
achievement on the goal of this project, for the most part may have to do with the uniqueness of 
the clinic. The clinic is managed mostly by volunteers, as a result, it was hard to reach all 
volunteers. There were some volunteers who only showed up on a monthly basis and others on a 
weekly basis. Since it was basically a free clinic, the volunteers were not required to follow any 
particular guidelines, hence, individuals chose whether or not to follow the screening 
CHRONIC HEPATITIS B SCREENING  31 
recommendations for this project. There was also a lot of resistance from providers who 
questioned the reason for changing practice especially since more screening would mean more 
money to be spent on testing for HBsAg.  
Interpretation 
 There were some in-service trainings provided to both physicians and nurse practitioners 
at the clinic in order to expose them to the latest update on chronic hepatitis B screening. One 
way to understand the worth of this project was to consider the benefits that early screening 
provided to patients. Patients who were screened were satisfied knowing their hepatitis B status. 
Early screening would be cost beneficial in the long run because it will save the cost of treating 
the sequelae of chronic hepatitis B. This would improve both patients’ and physicians’ 
satisfaction, and overall quality of life as there will be reduction in mortality and morbidity.  
Limitations 
 Several limitations were identified during the course of this project. This project took 
place at a free clinic, as a result, a lot of the patients seen at the clinic had not seen a provider in 
so many years, whereas some of these patients had co-morbid and chronic conditions that 
required more attention. Hence, chronic hepatitis B screening did not always become a top 
priority as a standard of care unless patients had symptoms. Owing to the uniqueness of this 
clinic, the findings might not be applicable to other clinics that were structured differently. 
Although there was an extra effort made to improve the screening rate as discussed earlier, this 
still did not help improve the screening rate because of the uniqueness of this clinic. For instance, 
this clinic utilized paper charts, there was no electronic health record making it difficult to flag a 
patient’s record as eligible for chronic hepatitis B screening.  
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 The sample size was also considered as a limitation. A review of 240 charts might not 
have been enough to generalize and to conclude that chronic hepatitis B screening had not been 
offered to eligible patients. The recommendation would be for future studies to target a larger 
audience in order to apply the results to other larger organizations.  
 Another limitation was the fact that only the HBsAg test was used, instead of the HBsAg, 
Anti-HBc and Anti-HBs. As a result, there would be missed opportunities to vaccinate 
susceptible individuals against HBV.  
Conclusions  
 Chronic hepatitis B virus remains a global epidemic where some regions of the world are 
affected more than others. Even though the United States is not among the highly endemic 
regions of hepatitis B, it is imperative to note that owing to the huge number of immigrants in the 
States from endemic nations/countries, that approximately 700,000 to 2.2 million persons have 
chronic hepatitis B virus (USPSTF, 2014). Since patients with chronic hepatitis B might not 
always present with symptoms and will probably transmit the disease unknowingly, screening 
therefore is highly recommended in high risk individuals as a way to decrease mortality and the 
many sequelae of the virus such as cirrhosis and hepatocellular carcinoma. The Order of Malta 
clinic sees a huge number of immigrants (about 90% of their patient population), hence, 
incorporating chronic hepatitis B screening as part of routine care for eligible patients is highly 
encouraged. The screening will help to identify chronic carriers of hepatitis B virus, including 
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Section VI. Other Information 
Funding/Cost 
Each HbsAg test costs $14.20 and the clinic leadership covered the cost of this test for 
eligible patients at the clinic who met the screening criteria. No other outside sources supported 
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Appendix B 




Australia and South Pacific All except Australia and New Zealand 
Middle East All except Cyprus and Israel  
Eastern Europe  Malta, Spain, and indigenous populations in 
Greenland 
North America Alaska natives and indigenous populations in 
northern Canada  
Mexico and Central America Guatemala and Honduras 
South America Ecuador, Guyana, Suriname, Venezuela, and 
Amazonian areas of Bolivia, Brazil, 
Colombia, and Peru 
Caribbean  Antigua and Barbuda, Dominica, Grenada, 
Haiti, Jamaica, St. Kitts and Nevis, St. Lucia, 
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Appendix C 
                 Hepatitis B Serologic Marker Interpretation (CDC 2014) 
HbsAg 













  - - - - Never infected and 
susceptible to infection 
+ + - - Chronic infection 
- + - + Recovered from past 
infection and immune 
+ + + - Acute infection 
- + - + Immune by natural 
infection 
- - - + Immune by hepatitis B 
vaccination 
- + - - Immune by natural 
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Appendix D 
DNP Statement of Non-Research Determination Form 
Title of Project:  
   Improving Chronic Hepatitis B Virus Screening at a Safety-Net Primary Care Clinic 
Brief Description of Project:  
Currently, at the Order of Malta clinic, patients eligible for chronic hepatitis B are 
not always screened following the CDC recommendations; this clinic screens 
symptomatic patients. Hence, a lot of patients eligible for screening are being missed, and 
since chronic HBV is usually asymptomatic, persons with chronic HBV can still transmit 
the disease to others unknowingly thereby posing additional threat to the general public. 
Therefore, the goal of this project is to improve chronic hepatitis B screening thereby 
addressing the gap between current and optimal screening. By so doing, more patients 
will be screened and those with a positive HBsAg will be treated in order to prevent or 
delay cirrhosis and hepatocellular carcinoma. Richmond, Sasadeusz, & Temple-Smith 
state that if chronic hepatitis B is diagnosed early and managed appropriately, that the 
risk of liver disease and hepatocellular carcinoma will be greatly reduced (2018). For the 
purposes of this project, we will be screening for chronic HBV using only the HBsAg 
blood test.  
D) Aim Statement:  
By October 2019, about 70% of eligible patients at the Order of Malta Clinic will 
be screened for chronic hepatitis B virus using the HbsAg blood test. Education was 
provided to physicians and nurse practitioners as a reminder on the CDC eligibility 
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criteria for screening. Healthcare providers were interviewed individually to gain insights 
to the barriers of screening for chronic HBV. 240 patients’ charts were randomly 
reviewed; pre-intervention education was provided and charts were once again reviewed 
post-intervention to determine the outcome and success rate.  
B) Description of Intervention:  
A 30 minutes poster presentation was provided to physicians, nurse practitioners and staff 
at the clinic. This was done over a course of 3-4 weeks at different times in order to reach 
multiple providers. This presentation covered the importance of screening for chronic 
HBV, the eligibility criteria and what test to order.  Also, healthcare providers were 
provided with a laminated copy of eligibility criteria/screening tool and list of countries 
of birth to screen for, as a quick reference guide (see appendix B). 
C) How will this intervention change practice?  
It will provide consistency among providers. By following the recommended screening  
guidelines of chronic hepatitis B virus, patients who are positive will be treated to avert 
or prevent the long-term complications of the virus and also prevent transmission to  
unaffected individuals. This will reduce health care cost in the long run and improve  
overall quality of life.  
D) Outcome measurements:  
Outcomes were measured based on the following: 
1. The number or percentage of patients screened before and after the intervention. 
2. Increase in screening eligible patients from baseline of roughly 33% to about 70% 
by October 2019.  
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3. Increase in providers’ knowledge of CDC guidelines of chronic hepatitis B 
screening. 
References: 
Richmond, J. A., Sasadeusz, J., & Temple-Smith, M. (2017). The Role of Primary Health 
Care in Hepatitis B Testing and Management: A Case Study. Journal of community 
health, 43(1), 38-47. 
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767201/  
 
 
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used: (http://answers.hhs.gov/ohrp/categories/1569)  
☐ X This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). Student may proceed with implementation. 
☐This project involves research with human subjects and must be submitted for IRB approval 
before project activity can commence. 
Comments:   
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST * 
 
Instructions: Answer YES or NO to each of the following statements: 
Project Title: Improving Chronic Hepatitis B Virus Screening at a Safety-
Net Primary Care Clinic  
 
YES NO 
The aim of the project is to improve the process or delivery of care with 
established/ accepted standards, or to implement evidence-based change. There is 
no intention of using the data for research purposes. 
X  
The specific aim is to improve performance on a specific service or program and is 
a part of usual care.  ALL participants will receive standard of care. 
X  
The project is NOT designed to follow a research design, e.g., hypothesis testing 
or group comparison, randomization, control groups, prospective comparison 
groups, cross-sectional, case control). The project does NOT follow a protocol that 
overrides clinical decision-making. 
X  
The project involves implementation of established and tested quality standards 
and/or systematic monitoring, assessment or evaluation of the organization to 
ensure that existing quality standards are being met. The project does NOT 
develop paradigms or untested methods or new untested standards. 
X  
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The project involves implementation of care practices and interventions that are 
consensus-based or evidence-based. The project does NOT seek to test an 
intervention that is beyond current science and experience. 
X  
The project is conducted by staff where the project will take place and involves 
staff who are working at an agency that has an agreement with USF SONHP. 
X  
The project has NO funding from federal agencies or research-focused 
organizations and is not receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be 
implemented to improve the process or delivery of care, i.e., not a personal 
research project that is dependent upon the voluntary participation of colleagues, 
students and/ or patients. 
X  
If there is an intent to, or possibility of publishing your work, you and supervising 
faculty and the agency oversight committee are comfortable with the following 
statement in your methods section: “This project was undertaken as an Evidence-
based change of practice project at X hospital or agency and as such was not 
formally supervised by the Institutional Review Board.”  
X  
 
ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an 
Evidence-based activity that does NOT meet the definition of research.  IRB review is not 
required.  Keep a copy of this checklist in your files.  If the answer to ANY of these questions 
is NO, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human 




STUDENT NAME (Please print): Uwaezu Joy Umeh 
Signature of Student: 
______________________________________________________DATE____________         
 
SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):   
Dr. Jo Loomis______________________________________________ 
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    Appendix E 
Evaluation Table 
Citation: Author(s), 
Date of publication 
& Title  
Design/Method Study Findings Appraisal  
Cheng, S., Li, E., & 
Lok, A. S. (2016). 
Predictors and 
Barriers to Hepatitis 






Screening for HBV is the most 
important first step in preventing 
cirrhosis, liver cancer and mortality. 
Level IIIA 
Abara WE, Qaseem 
A, Schillie S, 





Linkage to Care: 
Best Practice Advice 
From the American 
College of 
Physicians and the 













Screening in high-risk populations is 
the first step in identifying persons 
with chronic HBV infection, thereby 
reducing the burden and cost 
associated with HBV infection. 
 
Level IIIA 
Li, S., Sim, S-C., 
Lee, L., Pollack, 
H.J., Wyatt, L.C., 
Trinh-Shevrin, C., 





Behaviors in a 
Community-Based 
Sample and Chinese 
and Korean 





HBV screening rates are low among 
Chinese and Korean Americans but 
physician’s screening 
recommendation significantly 
increased screening rates.  
 
Level IIIA 
Ma, G.X., Fang, 
C.Y., Seals, B., 
Feng, Z., Tan, Y., 






There is a high prevalence of 
hepatitis b among Vietnamese 
Americans yet screening remained 
low and this could be attributed to 
lack of knowledge of HBV, personal 
Level IA 
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Nguyen, M.T., Tran, 









and cultural reasons but a 
community-based approach to 
screening, patient and provider 
education would help increase 
screening. 
Sriphanlop, P., 
Jandorf, L., Kairouz, 
C., Thelemaque, L., 
Shankar, H., & 
Perumalswami, P. 
(2014). Factors 
Related to Hepatitis 
B Screening among 
Africans in New 
York City 
Qualitative study Lack of knowledge of HBV and 
transmission mode, privacy, fear of 
disclosure and deportation if positive 
for HBV on screening were found to 
be some of the barriers preventing 
Africans in the U.S. from screening 
for HBV. 
Level IIIA 
Blanas, D., Nichols, 
K., Bekele, M., 
Shankar H., Bekele, 
S., Jandorf, L., 
Izzeldin, S., Ndiaye, 
D., Traore, A., 
Bassam, M., 
Perumalswami, P. 
(2015). Adapting the 




B Screening and 
Linkage to Care in 
New York City 
Qualitative study Religion, attitudes toward health, 
undocumented status, and fear of 
deportation were barriers to 
screening for HBV among West 
African Francophone immigrants 
Level IIIA 
Mitruka et al., 2018 Cross-sectional, 
retrospective 
analysis  
They found that among 32,017 
persons with valid test results, 4269 
were infected with unknown 
immune status, 937 were infected, 
16,481 were susceptible, and 10,186 
were immune, remaining 234 were 
not categorized. Their study found 
that the prevalence of hepatitis b 
infection among refugees was about 
10 times higher than the U.S. 
general population.  
Level IIIA 
Wright, C.M., 
Boudarene, L., Ha, 




The authors found that screening 
for chronic hepatitis B is cost-
effective, and that treatment 
Level IA 
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Hawkins, N. (2018). 
A Systematic 
















reduces hepatitis associated 
complications 
Campbell, B., 
Lopez, A., Liu, B., 
Bhuket, T., & Wong, 
R.J. (2018). A Pilot 
Program Integrating 
Hepatitis B Virus 
(HBV) Screening 
into an Outpatient 
Endoscopy Unit 
Improves HBV 
Screening Among an 
Ethnically Diverse 
Safety-Net Hospital.   
A pilot study, 
randomized 
controlled trial 
They identified barriers to 
screening for hepatitis b such as 
mistrust of providers by minority 
groups, lack of knowledge of 
HBV screening. This pilot study 
showed that HBV screening rates 
could be improved at safety-net 
clinics.  
Their recommendations therefore 
were that incorporating chronic 
HBV screening into a safety net 
clinic would be a great way to 
improve screening.     
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Restrospective review of charts
Individual interviews with MDs 
and NPs
Review of laboratory 
billing data
Low screening of chronic hepatitis B: 
Preliminary estimates suggest 30-
40% of eligible patients are screened










GANTT CHART 2018                                                 2019 
Stages of Project 
and DNP Course 
Work 



























-NURS 789 DNP 
Project 
NURS 795 DNP 
Implementation 
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Appendix H  

















Low hepatitis B 
screening rate at 































What When To whom How 
Meeting with 
academic advisor and 
committee member, 
Dr. Loomis and Dr. 
Rowniak 
As needed Advisor Email, zoom sessions  
Meeting with Clinic 
supervisors, 
administrator, and 
Director to discuss 
the project, staffing, 
and schedules 







Chart review with 
volunteer staff 





















































•Improvement of chronic hepatitis B 
screening
•Improved knowledge of hepatitis B 
screening guidelines
•Enhanced communiation between 
providers and patients
• To start treatment early if HBsAg 
positive
• Time consuming
• Missed opportunities to vaccinate 
susceptibe individuals since HBsAb 
will not be tested
• sample size
• overall cost saving
• consistency in following guidelines
• Training opportunities for 
providers
• Improve overall quality of life
Strength Weakness
ThreatsOpportunities
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Appendix K 
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Appendix L 
CQI Method/Data Collection Tool 
Interview Question by Domain (Fishbein et al. 1991) Construct (Michie et al. 2005) Summary of Mock Data 
Knowledge: 
How familiar are you with HBV screening 
eligibility requirements? 
 
Do you know what tests to order for 
someone who is eligible? 
 
What is the rate of screening done at the 
clinic? (in terms of test per eligible patient) 
 
What is the rate of chronic HBV infection 
identified at the clinic? 
 
Do you typically know the prevalence of 
HBV infection in your patients’ home 
countries? (including the Bay Area/United 
States) 
 
How do you think HBV screening can be 
important to patients and to our clinic/local 
community/beyond? 
 
- Knowledge: provider/intake nurse 
screening eligibility knowledge following 
clinic guidelines 
 
- Knowledge about scientific rationale: 
provider/intake nurse understanding of 
HBV prevalence, transmission, and 
potential for chronic infection; knowledge 
regarding chronic HBV potential 
complications; knowledge of decrease risk 
from HBV vaccination 
 
- Schemas + mindsets + illness 
representations: HBV infection 
representation (wide array), clinic 
population diversity (eg. last month 40% of 
patients presented from a country of origin 
in sub-Saharan Africa, where the prevalence 
of HBV is considered “high” by the CDC, 
warranting HBV screening) 
 
- Procedural Knowledge: screening process 
knowledge (how to order, which form to 
order, which test to order (HbsAg - blood), 




“I’m vaguely familiar insofar as knowing 
whether the majority of my patients are 
eligible/ineligible.” 
 
“I know the HBsAg is the usual test, but I’m 
not sure when the other blood tests should 
be used” 
 
“I have no idea about the rate of the clinic’s 
screening, but I know I probably under-
screen” 
 
“I know the HBV prevalence is high in 
Eritrea, but otherwise I’m not completely 
sure” 
 
“HBV screening is likely vital for our 
foreign patients who are visiting the country 
temporarily.  I’m unsure of the local 
impact” 
Intention: 
Do you feel that you need to assess HBV 
screening eligibility for every patient? Why 
or why not? 
 
Would you say there is a difference in 
assessment rate between patients with 
specific chief complaints and those 
presenting for health maintenance/follow-up? 
 
Does assessing HBV screening eligibility 
interfere with other goals of yours?  How 
much more time/resources would be needed 
to include HBV screening? 
 
- Intention: providers intend to provide 
underrepresented populations with optimal 
health care 
 
- Goal priority: provider goals (do they 
include preventative medicine/long term 
health management?) 
 
- Intrinsic motivation: provider’s natural 
stance towards HBV screening at clinic  
 
Skill: 
Do you know which form/where on the form 
to order the test? 
 
Do you have patients who refuse HBV 
screening?  If so, do you know why? 
 
- Skills: assess patient eligibility, 
recommend screening (interpersonal 
communication), ordering correct labs 
 
- Competence: competence in assessing 
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How do you go about addressing screening 
on a busy day vs. a non-busy day? 
 
How difficult is it to develop a screening 
eligibility assessment routine? 
 
Do you have any reminders regarding 
screening/other preventative medicine 
recommended screening? 
- Interpersonal skills: ability to 
communicate HBV screening 
recommendation rationale 
Environmental Constraints: 
To what extent do physical or resource 
factors facilitate or impede the assessment of 
eligibility? 
 
Are there tasks competing with the 
assessment of eligibility? 
 
How often is time a concern when it comes 
to screening assessment?  For cases where 
the visit does not have enough time, how 
often is that a great deal of time? (>20 
minutes) For cases where the visit has 
already gone over time, how much time is 
usually gone-over? 
 
Do you have the necessary resources to 
assess eligibility in all your patient 
interviews? 
- Resources/material resources: availability 
and management of resources related to 
screening (eg. availability of eligibility 
criteria, availability of other providers who 
can consult, availability of screening test 
forms) 
 
- Environmental stressors: environmental 
stressors perceived to influence screening 
assessment 
 
- Person x environment interaction: the 
interaction between the providers and the 
environment (eg. patients who have left 
work to make an appointment, patients with 
a history of failure to follow-up, patients 
with difficulty acquiring transportation) 
 
Social Influences: 
Do you feel like you have the support system 
to conduct screening eligibility assessment at 
each encounter? 
 
How often do you consult other 
physicians/resources per day (or other unit of 
time/resource)? 
 
Did you observe others evaluating screening 
eligibility? 
 
What is the overall climate of the clinic in 
regard to HBV screening? 
- Social support: whether providers have the 
social support from clinic 
administrative/opinion leaders to support 
the assessment. 
 
- Leadership: the degree to which opinion 
leaders/ providers hold in high esteem 
influence their performance of eligibility 
assessment  
 
- Organizational climate: the clinic’s overall 
attitude regarding HBV screening and 
whether it has the necessary tools/resources 
to facilitate screening for every patient 
 
- Learning/modeling: whether someone 
influential helps model the target behavior 
and influences providers in administration 
of screening eligibility at every patient 
encounter 
 
Mock Data Summary Example: (to be placed above the answers above) 
Provider Key Domains 
Engaged 
Overall theme(s) Representative quote(s) 
Jane Doe, MD Environmental 
context 
Provider often finds their 
patient encounters going 
over time focused on other 
health concerns. 
“I just don’t have the time to focus on other issues sometimes.  I do 
make a note of it and recommend the next provider assess for health 
care maintenance concerns including HTN, DM, and other 
screening”  
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Questions: Responses 
How familiar are you with HBV screening eligibility 
requirements? 
Vaguely familiar insofar as knowing whether the majority of my 
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Appendix M: Agency Approval Letter 
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Appendix N: USPSTF Grade Definitions: 
Grade Definition Suggestions for Practice 
A 
The USPSTF recommends the service. There is high certainty 
that the net benefit is substantial. 
Offer or provide this service. 
B 
The USPSTF recommends the service. There is high certainty 
that the net benefit is moderate or there is moderate certainty 
that the net benefit is moderate to substantial. 
Offer or provide this service. 
C 
The USPSTF recommends selectively offering or providing 
this service to individual patients based on professional 
judgment and patient preferences. There is at least moderate 
certainty that the net benefit is small. 
Offer or provide this service for selected patients 
depending on individual circumstances. 
D 
The USPSTF recommends against the service. There is 
moderate or high certainty that the service has no net benefit 
or that the harms outweigh the benefits. 
Discourage the use of this service. 
I 
Statement 
The USPSTF concludes that the current evidence is 
insufficient to assess the balance of benefits and harms of the 
service. Evidence is lacking, of poor quality, or conflicting, and 
the balance of benefits and harms cannot be determined. 
Read the clinical considerations section of USPSTF 
Recommendation Statement. If the service is offered, 
patients should understand the uncertainty about the 
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Appendix O: Screening tool; CDC’s Recommendation for Routine Testing and Follow-up for Chronic 
Hepatitis B Virus Infection 
Population Testing  Vaccination/Follw-up 
Persons born in regions of high and 
intermediate HBV endemicity (HBsAg 
prevalence 2%) 
Test for HBsAg, regardless of 
vaccination status in their country 
of origin, including immigrants, 
refugees, asylum seekers and 
internationally adopted children 
If HBsAg-positive, refer for medical 
management. If negative, assess for on-
going risk for hepatitis B and vaccinate if 
indicated 
US born persons not vaccinated as 
infants whose parents were born in 
regions with high HBV endemicity 
(8%) 
Test for HBsAg regardless of 
maternal HBsAg status if not 
vaccinated as infants in the United 
States 
If HBsAg-positive, refer for medical 
management. If negative, assess for on-
going risk for hepatitis B and vaccinate if 
indicated 
Injection-drug users  Test for HBsAg, as well as anti-
HBc or anti-HBs to identify 
susceptible persons 
1st vaccine dose should be given same 
visit as testing. Susceptible persons 
should complete a 3-dose hepatitis B 
vaccine series 
Men who have sex with men  Test for HBsAg, as well as anti-
HBc or anti-HBs to identify 
susceptible persons 
1st vaccine dose should be given same 
visit as testing. Susceptible persons 
should complete a 3-dose hepatitis B 
vaccine series 
Persons needing immunosuppressive 
therapy, including chemotherapy, 
immunosuppression related to organ 
transplantation, and 
immunosuppression for rheumatologic 
or gastroenterologic disorders 
Test for all markers of HBV 
infection (HBsAg, anti-HBc, and 
anti-HBs)  
Treat persons who are HBsAg-positive. 
Monitor closely persons who are anti-
HBc positive for signs of liver disease 
Persons with elevated ALT/AST of 
unknown etiology 
Test for HBsAg along with other 
appropriate medical evaluation 
Follow up as indicated 
Donors of blood, plasma, organs, 
tissues, or semen  
 
Test for HBsAg, anti-HBc, and 
HBV-DNA as required 
 
Hemodialysis patients Test for all markers of HBV 
infection (HBsAg, anti-HBc, and 
anti-HBs) 
Vaccinate against hepatitis B and 
revaccinate when serum anti-HBs titer 
falls below 10mIU/m 
All pregnant women Test for HBsAg during each 
pregnancy, preferably in the 1st 
trimester. 
Test at the time of admission for 
delivery if prenatal HBsAg test 
result is not available of if mother 
was at risk for infection during 
pregnancy 
If HBsAg positive, refer for medical 
management. To prevent perinatal 
transmission, infants of HBsAg-positive 
mothers and unknown HBsAg status 
mothers should receive vaccination and 
post-exposure immunoprophylaxis in 
accordance with recommendations and 
within 12 hours of delivery 
Infants born to HBsAg positive 
mothers 
Test for HBsAg and anti-HBs 1-2 
months after completion of at least 
3 doses of a licensed hepatitis B 
vaccine series (ie., at age 9-18 
months, generally at the next well-
child visit to assess effectiveness of 
post-exposure 
immunoprophylaxis). Testing 
should not be performed before age 
Vaccination in accordance with 
recommendations  
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9 months or within 1 month of the 
most recent vaccine dose 
Household, needle-sharing, or sex 
contacts of persons known to be 
HBsAg positive  
Test for HBsAg, as well as anti-
HBc or anti-HBs to identify 
susceptible persons 
1st vaccine dose should be given same 
visit as testing. Susceptible persons 
should complete a 3-dose hepatitis B 
vaccine series 
Persons who are the sources of blood 
or body fluids resulting in an exposure 
(e.g., needlestick, sexual assault) that 
might require post-exposure 
prophylaxis  
Test source for HBsAg 
 
Vaccinate healthcare and public safety 
workers with reasonably anticipated 
occupational exposures to blood or 
infectious body fluids. Provide post-
exposure prophylaxis to exposed person if 
needed 
HIV-positive persons  
 
Test for HBsAg, as well as anti-
HBc or anti-HBs to identify 
susceptible persons 
Vaccinate susceptible persons against 
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Appendix Q: Proforma 
Chronic Hepatitis B Project  
 Year 1 Year 2 Year 3 
Cost of HBsAg(a) $14.20 $15.90  $17.30  
Average time spent 
to order HBsAg (a) 
$22.50  24.33 $26.98 
Supplies(b&c) $250.00 $320 $410 
Cost of treating 
chronic hepatitis B (a) 
$761  $849 $950 
Cost of treating 
compensated cirrhosis 
(b)  
$227 $372 $428 
Cost of treating 
decompensated 
cirrhosis (b) 
$11,459 $13,238 $15,874 
Cost of treating 
hepatocellular 
carcinoma (b) 
$7,533 $8,422 $9,362 
Cost of treating liver 
transplant (b) 
$86,552 $98,265 $111,432 
Wages and benefits $445,000 $467,220 $488,315 
Gross revenue 1,100,450 1,321,480 1,492,112 
Expenses(a) $1,047.7 $1,209.23 $1,404.28 
Net profit(a) $654,402.3 $853,050.77 $1002,392.8 
The annual cost of treating one case of detected chronic hepatitis B including the test and 
physician time is estimated at $1047.7. Whereas, if no screening occurred, an asymptomatic 
patient could progress to decompensated cirrhosis, hepatocellular carcinoma which is 
estimated at $11,459 and $7,533 respectively. 
 
Option (a) is what this project is recommending, and the cost estimated here is per 1 case of 
detected chronic hepatitis B. 
Option (b) is the cost of treating complications from undetected chronic hepatitis B per case.  
 
 
 
 
 
 
 
 
